These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 35595609

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B, Levin J, Chang HY, Jones C, Alexander GC.
    JAMA Netw Open; 2018 Aug 03; 1(4):e181588. PubMed ID: 30646116
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. National trends in buprenorphine prescribing before and during the COVID-19 pandemic.
    Ali MM, Creedon TB, Jacobus-Kantor L, Sherry TB.
    J Subst Abuse Treat; 2023 Jan 03; 144():108923. PubMed ID: 36334383
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
    Nguyen T, Ziedan E, Simon K, Miles J, Crystal S, Samples H, Gupta S.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2214765. PubMed ID: 35648400
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
    Tilhou AS, Dague L, Saloner B, Beemon D, Burns M.
    JAMA Health Forum; 2022 Mar 01; 3(3):e220093. PubMed ID: 35977284
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.
    Stein BD, Saloner B, Kerber R, Sorbero M, Gordon AJ.
    Ann Emerg Med; 2022 May 01; 79(5):441-450. PubMed ID: 35305851
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D, Trotzky-Sirr R, Shooshtari A, Qato DM.
    Drug Alcohol Depend; 2022 Mar 01; 232():109291. PubMed ID: 35033953
    [Abstract] [Full Text] [Related]

  • 14. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.
    Knudsen HK, Hartman J, Walsh SL.
    Drug Alcohol Depend; 2022 Mar 01; 232():109336. PubMed ID: 35123365
    [Abstract] [Full Text] [Related]

  • 15. Decline in Prenatal Buprenorphine/Naloxone Fills during the COVID-19 Pandemic in the United States.
    O'Donoghue AL, Reichheld A, Anderson TS, Zera CA, Dechen T, Stevens JP.
    J Addict Med; 2022 Mar 01; 17(6):e399-e402. PubMed ID: 37934549
    [Abstract] [Full Text] [Related]

  • 16. Discontinuation of Buprenorphine Treatment for Opioid Use Disorder During the Coronavirus Disease-2019 Pandemic: A Multilevel Framework.
    Saloner B, Chang HY, Alexander GC, Stein BD.
    Med Care; 2023 Feb 01; 61(2):95-101. PubMed ID: 36630560
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R, Appajosyula S, Deximo C.
    Adv Ther; 2018 Apr 01; 35(4):457-466. PubMed ID: 29623562
    [Abstract] [Full Text] [Related]

  • 19. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM, Noor-E-Alam M, Mohite P, Islam MS, Modestino AS, Peckham AM, Young LD, Young GJ.
    J Subst Abuse Treat; 2021 Dec 01; 131():108416. PubMed ID: 34098294
    [Abstract] [Full Text] [Related]

  • 20. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
    Shcherbakova N, Tereso G, Spain J, Roose RJ.
    Ann Pharmacother; 2018 May 01; 52(5):405-414. PubMed ID: 29302989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.